Special Issue "Biological and Clinical Aspects of TGF-beta in Carcinogenesis"
Deadline for manuscript submissions: closed (30 September 2016) | Viewed by 91477
Interests: cancer–fibroblast crosstalk; tumor heterogeneity; small leucine-rich proteoglycans and TGF-beta; targeted cancer therapy; biomarkers
TGF-beta is a multipotent cytokine essential for normal development and immunity. Cells have complex molecular machineries to modulate the TGF-beta signaling on multiple levels. Deregulation of these safety mechanisms and general overexpression of TGF-beta has been frequently encountered in cancer. Indeed, TGF-beta has been associated to nearly all hallmarks of cancer progression. However and despite multiple advances, the mechanistic understanding TGF-beta biology in cancer is still difficult and confusing. Tumor-promoting and tumor-suppressive functions have both been observed in cell, time and context dependent manner. Despite these major gaps in our knowledge, numerous clinical trials have been started and completed with TGF-beta inhibitors yielding rather mixed results. The present Special Issue aims to outline our newest understanding of TGF-beta biological function in cancer as well as to review the most relevant clinical trials where TGF-beta served as a target. Our integrative understanding of both aspects should contribute to a clearer picture concerning the open questions and clinical perspectives of TGF-beta in carcinogenesis.
Dr. Andrei Turtoi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- TGF-beta and SMAD signaling
- stem cells
- clinical trials